Indivior is halting Opvee promotion after a New York settlement. Critics say the overdose drug is overpriced, risky, and no ...

Good morning. The FDA’s top drug regulator posted a highly unusual critique of a drug on his personal LinkedIn account ...

Is the FDA's top drug regulator, trying to exact revenge on a prominent Wall Street investor after a run-in with him six ...

After the last meeting of the CDC’s Advisory Committee on Immunization Practices, it’s clear that ending universal hepatitis ...

AstraZeneca plans to list its shares in New York while keeping its London listing, a move that could allow easier access to ...

It’s the question biotech investors were wagging about all Monday after Tidmarsh used his personal LinkedIn page to raise ...

A federal judge in Texas threw out a Biden-era rule last week that would have ramped up federal audits of private Medicare ...

Study finds 99% of all heart attacks, heart failure, or strokes occur in people with "suboptimal" blood pressure, cholesterol ...

GSK announced that Luke Miels, the company’s chief commercial officer, will take over as CEO on Jan. 1, replacing Emma ...

In today's Morning Rounds newsletter, burning questions on MMR vaccines, a perimenopause business boom, and more.

Lisa Suennen: "If this is going to make it a lot more expensive to get the same outcome, that is not a good investment." ...

The Danish company Genmab plans to buy Merus, the maker of a promising head and neck cancer drug, in a deal worth roughly $8 ...